Clinical Trials Snapshot

Natural Killer Cells and Bortezomib to Treat Cancer

Cell Therapy Next, May 2019
A phase 1, non-randomized, open-label, dose-escalation interventional study to evaluate the safety and the anti-tumor effects of escalating doses of…

Clinical Trials Snapshot

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma

Cell Therapy Next, May 2019
Phase 1 trial to find the largest effective and safe dose of GD2-CAR NKT cells (GINAKIT cells) and evaluate their effect on the tumor, how long they…

Clinical Trials Snapshot

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

Cell Therapy Next, May 2019
Phase 1 open-label trial examining the feasibility and safety of combining CIML NK cells with the donor lymphocyte infusion approach to significantly…

Clinical Trials Snapshot

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

Cell Therapy Next, May 2019
Phase 1, open label, multinational (EU/US) trial to assess the safety and clinical activity of NKR-2 treatment administered 3 times with a 2-week…

Cover Story

‘A Moment of Marvel’ in Manhattan Brings a Revolution in CAR T-Cell Therapy

Cell Therapy Next, May 2019
When the first flow cytometry analysis was run after a CAR T-cell therapy, showing no evidence of leukemia, Michel Sadelain, MD, PhD, and Isabelle

FDA News

P-BCMA-101 receives orphan drug designation for multiple myeloma

May 15, 2019
The FDA has granted orphan drug status to P-BCMA-101, a cell-based immunotherapy for the treatment of relapsed or refractory multiple myeloma…

Meeting News

Targeting mutations a 'complex' must in cell therapy for solid tumors

May 15, 2019
PHILADELPHIA — Effectively treating solid epithelial cancers will require targeting a patient’s somatic cancer mutations, leading to…

Meeting News

Outpatient CAR T-cell therapy possible if done earlier

May 13, 2019
PHILADELPHIA — Chimeric androgen receptor T-cell therapy has a reputation as a game-changing therapy with a hefty price tag. However, as CAR…

Feature

Costs, lengths of stay after CAR T-cell therapy greater for younger patients

May 10, 2019
Two studies presented at this year’s Transplantation & Cellular Therapy Meetings provided new insights into treatment costs and hospital…

HemOnc Today, Cell Therapy Next win awards in health care publishing competition

May 2, 2019
HemOnc Today and Cell Therapy Next received awards in the American Society of Health Care Publication Editors (ASHPE) Awards Competition. …

In the Journals

CAR T-cell therapy bb2121 shows promising efficacy, manageable toxicity in multiple myeloma

May 1, 2019
A chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen produced high response rates with manageable toxicity among patients…

Trend Watch

Medicare’s proposed CAR T reimbursement increase ‘woefully inadequate’

April 30, 2019
CMS has announced a proposed 15% increase in the amount it would reimburse hospitals for inpatient CAR T-cell therapy for Medicare patients. The…

FDA News

FDA gives orphan drug status to AUTO3 for ALL

April 25, 2019
The FDA has granted orphan drug status to AUTO3, a cell-based immunotherapy for the treatment of acute lymphoblastic leukemia. AUTO 3 (Autolus…

Treatment Toxicities: Present, but Manageable

Cell Therapy Next, April 2019
Frederick L. Locke, MD
In this installment of In Practice, Frederick L. Locke, MD, Co-Leader of the Immunology Program and Director of the Immune Cell Therapy Program at…

Clinical Trials Snapshot

Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia

Cell Therapy Next, April 2019
Phase 1, first-in-human, open-label, dose-finding study of UCART123 administered intravenously to patients with acute myeloid leukemia, followed by a…

Feature

Registry Could be ‘Invaluable’ for Tracking Long-term CAR T-cell Therapy Outcomes

Cell Therapy Next, April 2019
The Center for International Blood and Marrow Transplant Research, through an alliance with Novartis, aims to track the long-term outcomes of…

Clinical Trials Snapshot

Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma

Cell Therapy Next, April 2019
Pilot open-label study estimating the feasibility, safety, and efficacy of intravenously administered, RNA electroporated autologous T cells…

Cover Story

Life at City of Hope: ‘It’s Always a Great Day to Cure Cancer.’

Cell Therapy Next, April 2019
Walking between the wishing trees as one enters City of Hope, it is easy to comprehend what patients and physicians alike mean when they describe the…

Clinical Trials Snapshot

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Cell Therapy Next, April 2019
Phase 1 trial examining the side effects and best dose of B-cell maturation antigen (BCMA)-chimeric antigen receptor (CAR) T-cells when combined with…

Clinical Trials Snapshot

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

Cell Therapy Next, April 2019
Phase 1, open-label study of the safety and efficacy of anti-CD22 chimeric antigen receptor (CAR) T-cell therapy in young patients with certain…